Compare Cytokinetics Inc (CYTK) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Williams-Sonoma, Inc. — how do they compare? Cytokinetics Inc trades at $62.69 (market cap $8.62B), while Williams-Sonoma, Inc. trades at $241.16 (market cap $28.15B). The key difference: Williams-Sonoma, Inc. is far larger — about 3.3× Cytokinetics Inc's market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Williams-Sonoma, Inc. for 59 Days on average.
| CYTK | WSM | |
|---|---|---|
Market Cap | $8.62B | $28.15B |
Volume | 2,594,626 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $251.81 |
52-Week Low | $54.76 | $168.64 |
Typical Hold Time | 19 Days | 59 Days |
Enterprise Value | $8.72B | $28.65B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
Williams-Sonoma (WSM) trades at $241.75, up 0.54% on the day, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.10 surpassing the $2.08 expectation. Revenue for 2025 was $7.71 billion, with a robust net income margin of 14.73% and high ROE of 54.96%. Recent news highlights market share gains and profitability improvements, including a new Pottery Barn collaboration and store expansion.
The outlook for WSM is positive, driven by earnings momentum, margin strength, and strategic initiatives. However, risks include competitive pressures in home furnishings and sensitivity to housing market trends. Analyst consensus is a buy with a $246.31 price target, suggesting modest upside from current levels, supported by institutional confidence and dividend declarations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
